Phio Pharmaceuticals shares are trading higher after the company received a patent in South Korea that covers the INTASYL RXI-185 compound.
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals shares are trading higher after the company received a patent in South Korea for the INTASYL RXI-185 compound.
June 18, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals shares are experiencing an upward trend following the announcement of a new patent in South Korea for their INTASYL RXI-185 compound.
The new patent in South Korea for the INTASYL RXI-185 compound is a significant milestone for Phio Pharmaceuticals, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100